Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03996291 · ClinicalTrials.gov registry record · Phase 2
Long Term Safety and Efficacy Study of Tolebrutinib (SAR442168) in Participants With Relapsing Multiple Sclerosis
A Phase 2 study, sponsored by Sanofi.
- Completed
- Registry status
- Phase 2
- Development phase
- 125
- Enrollment target
NCT03996291 is a Phase 2 study that has completed, run by Sanofi. The registered enrollment target is 125 participants.
The verdict
NCT03996291, a Phase 2 study, has completed, sponsored by Sanofi.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 125 participants
- Enrollment target
Study Summary
Primary Objective: To determine the long-term safety and tolerability of SAR442168 in RMS participants Secondary Objective: To evaluate efficacy of SAR442168 on disease activity, assessed by clinical and imaging methods
Interventions
- DRUG Tolebrutinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 125 participants |
| Start Date | 2019-09-23 |
| Est. Completion | 2024-11-26 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03996291
The ClinicalTrials.gov registry entry for NCT03996291 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 125 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sanofi, which has 713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Tolebrutinib is the first listed.
NCT03996291 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03996291 about?
NCT03996291 is a clinical study titled "Long Term Safety and Efficacy Study of Tolebrutinib (SAR442168) in Participants With Relapsing Multiple Sclerosis". Primary Objective: To determine the long-term safety and tolerability of SAR442168 in RMS participants Secondary Objective: To evaluate efficacy of SAR442168 on disease activity, assessed by clinical and imaging methods
What is the current status of trial NCT03996291?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 125 participants. The study started on 2019-09-23. Estimated completion is 2024-11-26.
What interventions are being tested in trial NCT03996291?
The interventions under investigation include: Tolebrutinib (DRUG).
Who is sponsoring clinical trial NCT03996291?
This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.